0 6 Nitric nitric JJ 7 12 oxide oxide NN 13 22 decreases decrease VBZ 23 39 cytokine-induced cytokine-induced JJ 40 51 endothelial endothelial JJ 52 62 activation activation NN 62 63 . . . 64 70 Nitric nitric JJ 71 76 oxide oxide NN 77 88 selectively selectively RB 89 96 reduces reduce VBZ 97 108 endothelial endothelial JJ 109 119 expression expression NN 120 122 of of IN 123 131 adhesion adhesion NN 132 141 molecules molecule NNS 142 145 and and CC 146 161 proinflammatory proinflammatory JJ 162 171 cytokines cytokine NNS 171 172 . . . 174 176 To to TO 177 181 test test VB 182 185 the the DT 186 196 hypothesis hypothesis NN 197 201 that that IN 202 208 nitric nitric JJ 209 214 oxide oxide NN 215 216 ( ( ( 216 218 NO no NN 218 219 ) ) ) 220 226 limits limit VBZ 227 238 endothelial endothelial JJ 239 249 activation activation NN 249 250 , , , 251 253 we we PRP 254 261 treated treat VBD 262 281 cytokine-stimulated cytokine-stimulated JJ 282 287 human human JJ 288 297 saphenous saphenous JJ 298 302 vein vein NN 303 314 endothelial endothelial JJ 315 320 cells cell NNS 321 325 with with IN 326 333 several several JJ 334 336 NO no NN 337 343 donors donor NNS 344 347 and and CC 348 356 assessed assess VBD 357 362 their their PRP$ 363 370 effects effect NNS 371 373 on on IN 374 377 the the DT 378 387 inducible inducible JJ 388 398 expression expression NN 399 401 of of IN 402 410 vascular vascular JJ 411 415 cell cell NN 416 424 adhesion adhesion NN 425 435 molecule-1 molecule-1 NN 436 437 ( ( ( 437 443 VCAM-1 vcam-1 NN 443 444 ) ) ) 444 445 . . . 446 448 In in IN 449 450 a a DT 451 474 concentration-dependent concentration-dependent JJ 475 481 manner manner NN 481 482 , , , 483 485 NO no NN 486 495 inhibited inhibit VBD 496 507 interleukin interleukin NN 508 509 ( ( ( 509 514 IL)-1 il)-1 NN 515 531 alpha-stimulated alpha-stimulated JJ 532 538 VCAM-1 vcam-1 NN 539 549 expression expression NN 550 552 by by IN 553 558 35-55 35-55 CD 558 559 % % NN 560 562 as as IN 563 573 determined determine VBN 574 576 by by IN 577 581 cell cell NN 582 589 surface surface NN 590 596 enzyme enzyme NN 597 609 immunoassays immunoassay NNS 610 613 and and CC 614 618 flow flow NN 619 628 cytometry cytometry NN 628 629 . . . 630 634 This this DT 635 645 inhibition inhibition NN 646 649 was be VBD 650 660 paralleled parallel VBN 661 663 by by IN 664 671 reduced reduce VBN 672 680 monocyte monocyte NN 681 689 adhesion adhesion NN 690 692 to to TO 693 704 endothelial endothelial JJ 705 715 monolayers monolayer NNS 716 718 in in IN 719 728 nonstatic nonstatic JJ 729 735 assays assay NNS 735 736 , , , 737 740 was be VBD 741 751 unaffected unaffected JJ 752 754 by by IN 755 759 cGMP cgmp NN 760 769 analogues analogue NNS 769 770 , , , 771 774 and and CC 775 778 was be VBD 779 793 quantitatively quantitatively RB 794 801 similar similar JJ 802 807 after after IN 808 819 stimulation stimulation NN 820 822 by by IN 823 829 either either CC 830 834 IL-1 il-1 NN 835 840 alpha alpha NN 840 841 , , , 842 846 IL-1 il-1 NN 847 851 beta beta NN 851 852 , , , 853 857 IL-4 il-4 NN 857 858 , , , 859 864 tumor tumor NN 865 873 necrosis necrosis NN 874 880 factor factor NN 881 882 ( ( ( 882 885 TNF TNF NNP 886 891 alpha alpha NN 891 892 ) ) ) 892 893 , , , 894 896 or or CC 897 906 bacterial bacterial JJ 907 925 lipopolysaccharide lipopolysaccharide NN 925 926 . . . 927 929 NO no NN 930 934 also also RB 935 944 decreased decrease VBD 945 948 the the DT 949 960 endothelial endothelial JJ 961 971 expression expression NN 972 974 of of IN 975 980 other other JJ 981 990 leukocyte leukocyte NN 991 999 adhesion adhesion NN 1000 1009 molecules molecule NNS 1010 1011 ( ( ( 1011 1021 E-selectin E-selectin NNP 1022 1025 and and CC 1026 1028 to to TO 1029 1030 a a DT 1031 1037 lesser less JJR 1038 1044 extent extent NN 1044 1045 , , , 1046 1059 intercellular intercellular JJ 1060 1068 adhesion adhesion NN 1069 1079 molecule-1 molecule-1 NN 1079 1080 ) ) ) 1081 1084 and and CC 1085 1095 secretable secretable JJ 1096 1105 cytokines cytokine NNS 1106 1107 ( ( ( 1107 1111 IL-6 IL-6 NNP 1112 1115 and and CC 1116 1120 IL-8 il-8 NN 1120 1121 ) ) ) 1121 1122 . . . 1123 1133 Inhibition Inhibition NNP 1134 1136 of of IN 1137 1147 endogenous endogenous JJ 1148 1150 NO no NN 1151 1161 production production NN 1162 1164 by by IN 1165 1188 L-N-monomethyl-arginine L-N-monomethyl-arginine NNP 1189 1193 also also RB 1194 1201 induced induce VBD 1202 1205 the the DT 1206 1216 expression expression NN 1217 1219 of of IN 1220 1226 VCAM-1 vcam-1 NN 1226 1227 , , , 1228 1231 but but CC 1232 1235 did do VBD 1236 1239 not not RB 1240 1247 augment augment VB 1248 1264 cytokine-induced cytokine-induced JJ 1265 1271 VCAM-1 vcam-1 NN 1272 1282 expression expression NN 1282 1283 . . . 1284 1291 Nuclear nuclear JJ 1292 1298 run-on run-on JJ 1299 1305 assays assay NNS 1305 1306 , , , 1307 1319 transfection transfection NN 1320 1327 studies study NNS 1328 1333 using use VBG 1334 1341 various various JJ 1342 1348 VCAM-1 vcam-1 NN 1349 1357 promoter promoter NN 1358 1366 reporter reporter NN 1367 1371 gene gene NN 1372 1382 constructs construct NNS 1382 1383 , , , 1384 1387 and and CC 1388 1403 electrophoretic electrophoretic JJ 1404 1412 mobility mobility NN 1413 1418 shift shift NN 1419 1425 assays assay NNS 1426 1435 indicated indicate VBD 1436 1440 that that IN 1441 1443 NO no NN 1444 1453 represses repress VBZ 1454 1460 VCAM-1 vcam-1 NN 1461 1465 gene gene NN 1466 1479 transcription transcription NN 1479 1480 , , , 1481 1483 in in IN 1484 1488 part part NN 1488 1489 , , , 1490 1492 by by IN 1493 1503 inhibiting inhibit VBG 1504 1512 NF-kappa NF-kappa NNP 1513 1515 B. B. NNP 1516 1518 We we PRP 1519 1526 propose propose VBP 1527 1531 that that IN 1532 1534 NO no NN 1534 1536 ’s 's POS 1537 1544 ability ability NN 1545 1547 to to TO 1548 1553 limit limit VB 1554 1565 endothelial endothelial JJ 1566 1576 activation activation NN 1577 1580 and and CC 1581 1588 inhibit inhibit VB 1589 1597 monocyte monocyte NN 1598 1606 adhesion adhesion NN 1607 1610 may may MD 1611 1621 contribute contribute VB 1622 1624 to to TO 1625 1629 some some DT 1630 1632 of of IN 1633 1636 its its PRP$ 1637 1652 antiatherogenic antiatherogenic JJ 1653 1656 and and CC 1657 1673 antiinflammatory antiinflammatory JJ 1674 1684 properties property NNS 1685 1691 within within IN 1692 1695 the the DT 1696 1702 vessel vessel NN 1703 1707 wall wall NN 1707 1708 . . .